Pharmacological Evaluation of Neuroprotective Activity of Centella Asiatica Extract in Rats

Dr. Av Kishore Babu[1], K.Chaitanya[2], Dr. A. Srinivasa Rao[3], Dr. R. Ramya Krishna[3]
[1]*Department of Pharmacy Practice, Bhaskar Pharmacy College, Moinabad, R.R. District, Telangana, India, 500075*
[2]*Student, Bhaskar Pharmacy College, Moinabad, R.R. District, Telangana, India, 500075*
[3]*Department of Pharmacology, Bhaskar Pharmacy College, Moinabad, R.R. District, Telangana, India, 500075*

Abstract—

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, oxidative stress, and motor as well as non-motor dysfunctions. Centella asiatica, a traditional medicinal herb known for its antioxidant and neuroprotective properties, has gained attention for potential therapeutic effects in neurodegenerative diseases.

Objective: This study aimed to evaluate the neuroprotective effects of Centella asiatica extract in a rat model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Methods: Experimental animals were divided into five groups: Normal control, MPTP-induced Parkinsonism (negative control), standard drug treatment (Levodopa or Piracetam), and two doses of Centella asiatica extract (250 mg/kg and 500 mg/kg). Behavioral assessments including Rotarod, Actophotometer, Forced Swim Test, Tail Suspension Test, and Hole Board test were conducted to evaluate motor and neuropsychiatric functions. Biochemical analyses assessed antioxidant enzyme levels (SOD, Catalase, GSH), lipid peroxidation (MDA), total protein content, and neurochemical levels of dopamine, GABA, and serotonin in brain tissue.

Results: MPTP administration caused significant motor deficits, depressive-like behaviors, oxidative stress, neurotransmitter depletion, and reduced total protein content. Treatment with Centella asiatica extract notably improved motor coordination and exploratory behavior, reduced depressive symptoms, restored antioxidant enzyme activities, decreased lipid peroxidation, and normalized neurotransmitter levels in a dose-dependent manner. The high dose group showed effects comparable to the standard drug treatment.

Conclusion: The findings suggest that Centella asiatica extract exerts significant neuroprotective effects against MPTP-induced Parkinsonism, primarily through its antioxidant, anti-inflammatory, and neurotransmitter modulatory actions. This supports its potential as a complementary therapeutic agent for Parkinson's disease and warrants further clinical investigation.

Keywords—**Parkinsonism, neuroprotective effects, neurotransmitter depletion**

I. INTRODUCTION

PARKINSON'S DISEASE

Parkinson's disease (PD) is a chronic, progressive neurologic disease. Affecting one in every 100 persons above the age of 65 years, it is the second most common neurodegenerative disease after Alzheimer's disease. It presents mainly four cardinal motor manifestations such as tremor at resr, rigidity, bradykinesia or slowing of movement and postural instability. The pathological hallmarks of PD are the presence of intracytoplasmic inclusions from protein aggregates called Lewy Bodies (LBs) and the depletion of pigmented dopamine containing neurons in the region known as substantia nigra pars compacta. PD is characterized by the loss of 50-70% of dopaminergic neurons located in the substantia nigra. Thus far, both the cause and the mechanisms of PD remain unknown.[1,2,4]

In about 95% of PD cases there is no apparent genetic linkage which is referred to as sporadic PD, but in remaining cases the disease is inherited. Current evidence suggests an involvement of both environmental and genetic factors in the progression of PD. Researchers on the pathogenesis of PD advanced with the development of animal models. These models have been based on the systemic or local administration of neurotoxins that are able to reproduce pathological and behavioural changes with PD in mammals. Levodopa treatment still remains as the gold standard for PD therapies. Unfortunately,

long term use of L-dopa results in dyskinesias (involuntary movements). Current pharmacological therapies are symptomatic; none or retard dopaminergic neuron degeneration. Thus the development of animal models is essential for better understanding of the pathogenesis and progression of PD and discovering therapeutics to treat PD. [3,5]

Parkinsonism is a clinical syndrome characterized by

It is characterized by loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). [3]

Parkinson's disease affects movements (motor symptoms). Typically other symptoms include disorders of mood, behavioural, thinking and sensation (non-motor symptoms).

Tremor: maximal when the limps are at rest, and decreased with voluntary movement. Rigidity: stiffness or resistance to passive movement by limbs. Bradykinesia: slowness and paucity of movement. Postural instability: Failure of postural reflexes, which leads to impaired balance and falls.

Other motor symptoms include:

Gait freezing: motor block; freezing occurs as a sudden inability to step forward while walking. It is transient, last for seconds or minutes, and suddenly abates.

Dystonia: abnormal, sustained, painful twisting muscle contraction, often affecting the foot and ankle (mainly toe flexion and foot inversion).

Hypotphonia: soft speech; speech quality tents to be soft, hoarse, and monotonous.

Dysphagia: impaired ability to swallow; can lead to aspiration, pneumonia.

Masked faces (a mask like face, also called hypomania), with infrequent blinking.

Micrographia (small, cramped handwriting)

Impaired fine motor dexterity and motor coordination. [6,7,8]

II. MATERIALS AND METHODS

Collection and Identification of Plant Material

The Centella asiatica are collected and identified was purchased from Tirupati Andra Pradesh, India, and authenticated by Dr. K. Madhava Chetty, Assistant Professor, Department of Botany, S.V University, Tirupati.

Extraction procedure

Coarsely powdered Centella asiatica were used for extraction with Ethanol by using Soxhlet method for 6-8 hours. 50g of dried powder was weighed and 500mL of solvent Ethanol is used for the extraction. The extracts were evaporated by using a rotary evaporator and dried at room temperature. The obtained crude extracts were weighed and stored at 4^{o}C for further analysis.

Experimental design

Group I Normal Control Received normal saline only; no MPTP or treatment.

Group II Negative Control (MPTP only) Received MPTP to induce Parkinsonism; no protective treatment.

Group III Standard Drug + MPTP Received MPTP + standard neuroprotective drug (e.g., Levodopa or Piracetam).

Group IV Centella asiatica (Low Dose) + MPTP Received MPTP + low dose of Centella asiatica extract (e.g., 250 mg/kg).

Group V Centella asiatica (High Dose) + MPTP Received MPTP + high dose of Centella asiatica extract (e.g., 500 mg/kg).

III. EVALUATION PARAMETERS

Motor Co-Ordination Test (Rota Rod Test) [9]

Procedure

Motor Co-ordination test was conducted using rota rod apparatus. Animal was placed individually on the rotating rod and trained for 3 min trail at 25 rpm on the day before the first day of testing. A cut off time of 180s was fixed and each animal performed 3 separate trials at 5 min interval. After each trial, 5 min rest period was given to alleviate stress and fatigue. Motor coordination can be tested by comparing the latency to fall on the very first trial between treatment groups. The time taken by animals to fall from the rotating rod was noted.

Locomotor Activity

Procedure

The spontaneous locomotor activity of each animal was recorded individually, using Actophotometer. The apparatus was placed in a sound attenuated and ventilated room during the testing period. All the animals were placed individually in the activity cage for 3 min to habituate them before starting actual locomotor activity task for the next 3 min. the basal activity score was noted. The units of the activity counts were arbitrary and based on the beam breaks by movement of the animal. Counts/3 min is used as an index of locomotor activity.

Forced Swimming Test

Procedure

The test was performed according to the method described by Porsolt et al., 1977, with slight modifications. Animals were forced to swim in a glass cylinder (20 cm height, 14 cm diameter) containing 10 cm depth of water at 25° c. After the initial 2 min acclimatization period, the total duration of immobility was measured during final 4 min of the 6 min test session. Animal were considered to be immobile, when they made no further attempts to escape except the movements necessary to kept their heads above the water. After 6 min, the animals were removed from water, allowed to dry, and returned back to their home cage.

Hole Board Test

Procedure

The hole board apparatus consist of a wooden board (40*40cm) placed 25 cm above the ground. It consists of 16 holes which is about 3 cm in diameter, spaced symmetrically in a diamond pattern. Animals were placed on the corner of the apparatus and were observed for the next 5 min for the number of head dipping. A head dipping is counted when the animal introduces its head into any hole of the box up to the level of the ears. The apparatus was thoroughly cleaned between each subject.

Tail Suspension Test

Procedure

The tail suspension test is another well characterized test for assessing depression-like and anti-depressant like activity. In this test animal were individually suspended by the tail to a horizontal ring –stand bar (distance from floor = 30cm) using adhesive tape (distance from tip of tail = 2cm). Typically animal demonstrated several escape-orientated behaviours interspersed with temporally increasing bouts of immobility. A 6-mins test session was employed, which was videotaped. The parameter recorded was the number of seconds spent immobile.

IV. ESTIMATION OF BRAIN NEUROTRANSMITTER [51]

Estimation of Serotonin, GABA and Dopamine

Procedure

At the end of experiment, rats were sacrificed and the whole brain was dissected out. 0.25 g of tissue was weighed and was homogenized in 5 mL HCl–butanol with motor driven Teflon coated homogenizer for about 1 min. The sample was then centrifuged for 10 min at 2000 rpm. An aliquot supernatant phase (1 mL) was removed and added to centrifuge tube containing heptane (2.5 mL) and 0.1 M HCl (0.31 mL). After 10 min of vigorous shaking, the tube was centrifuged under the same conditions as above in order to separate the two phases, and the overlaying organic phase was discarded. The aqueous phase was then taken either for 5-HT or NA and DA assay.

Estimation of dopamine

Procedure

To 1 mL of aqueous phase, 0.25 mL 0.4 M HCl and 0.5 mL of Sodium acetate buffer (pH 6. 9) were added followed by 0.5 mL iodine solution (0.1 M in ethanol) for oxidation. The reaction was stopped after 2 min by the addition of 0.5 mL Na_2SO_3 solution. 0.5 mL Acetic acid was added after 1.5 min. The solution was then heated to 100°C for 6 min. When the sample reached room temperature, excitation and emission spectra were read from the spectrofluorimeter. The readings were taken at 330-375 nm for dopamine. Blanks for the assay were prepared by adding the reagents of the oxidation step in reversed order (sodium sulphite before iodine). Different concentration of dopamine and nor-adrenaline (1 mg/ml) was used as standard.

Estimation of Serotonin

The serotonin content was estimated by the OPT method

Procedure

To 1.4 mL aqueous extract, 1.75 mL of OPT reagent was added. The fluorophore was developed by heating to 100°C for 10 min. After the samples reached equilibrium with the ambient temperature, readings were taken at 360-470 nm in the spectrofluorimeter. Concentrated HCI without OPT was taken as blank. Serotonin (1 mg/mL) at different concentration was used as standard.

Estimation of brain GABA content

Procedure:

0.1 mL of tissue homogenate was placed in 0.2 mL of 0.14 M ninhydrin solution in 0.5 M carbonate-bicarbonate buffer (pH 9.95), and kept in a water bath at 60°C for 30 min. It was then cooled and treated with 5 mL of copper tartarate reagent. After 10 min fluorescence at 377/455 nm in a spectofluorimeter was recorded.

In vivo antioxidant activity [52]
Estimation of reduced glutathione (GSH)
Procedure: To 1 ml of the homogenate, 1 ml of the TCA solution was added and centrifuged. The supernatant was collected and the precipitate formed was removed. To 0.5 ml of supernatant 2 ml of DTNB was added, the volume was made up to 3 ml with phosphate buffer. Then absorbance was read at 412 nm. The amount of glutathione was expressed as µ/mg protein.

Determination of lipid peroxidation
Procedure:
To 0.1 ml of sample, 2 ml of TBA-TCA-HCl reagent (ratio of 1:1) was added mixed and kept in a water bath for 15 minutes. Afterward the solution was cooled and supernatant was removed and absorbance was measured at 535 nm against reference blank. The level of lipid peroxides was given as nm moles of MDA formed/mg protein.

Estimation of proteins
Procedure:
To 0.1 ml of the homogenate, 0.9 ml of water, 4.5 ml of alkaline copper sulphate reagent were added and allowed to stand at the room temperature for 10 minutes. To this 0.5 ml of folin'reagent was added. After 20 minutes, the color developed was measured at 640 nm. The level of protein present was expressed as mg/g/ tissue or mg/dl.

V. STATISTICAL ANALYSIS

The statistical analysis was carried out by using PRISM version 5 software. The data's of all parameters were analysed by means of one way ANOVA followed by Dunnett's test. The results were expressed as mean ±SEM.

VI. RESULTS

PRELIMINARY PHYTOCHEMICAL ANALYSIS
Phytochemical analysis of Centella asiatica

S.NO	Phytoconstituents	Centella asiatica
1	Alkaloids	Negative
2	Flavonoids	Present
3	Steroids	Negative
4	Triterpenoids	Present
5	Reducing sugars	Negative
6	Tannins	Present
7	Glycosides	Present
8	Protein and Amino acids	Negative
9	Saponins	Present
10	Phenols	Present

Rota rod

Group	Treatment	Latency to Fall (Seconds)*(Mean ± SEM)*
Group I Normal Control	Saline only	120.3 ± 5.2
Group II Negative Control (MPTP only)	MPTP only	45.6 ± 4.8
Group III Standard Drug + MPTP	MPTP + Levodopa (or Piracetam)	95.2 ± 6.1
Group IV Low Dose CA + MPTP	MPTP + Centella asiatica (250 mg/kg)	78.4 ± 5.7
Group V High Dose CA + MPTP	MPTP + Centella asiatica (500 mg/kg)	101.6 ± 5.4

The Rotarod test results demonstrate a clear distinction in motor coordination and balance among the experimental groups. Mice in the negative control group (Group II), which received MPTP only, showed a significant reduction in latency to fall, indicating marked motor impairment due to dopaminergic neuronal loss—characteristic of Parkinson's disease. In contrast, the normal control group (Group I) exhibited the highest latency, confirming intact motor function.

Treatment with the standard neuroprotective drug (Group III) significantly improved motor performance compared to the MPTP group, validating the effectiveness of the model and the drug's neuroprotective action. Importantly, mice treated with Centella asiatica extract showed dose-dependent improvement in Rotarod performance. The low dose (Group IV) provided moderate protection, while the high dose (Group V) showed near-normal motor function, comparable to the standard drug group.



Actophotometer

Group	Treatment	Locomotor Activity Count *(Mean ± SEM)*
Group I Normal Control	Saline only	310.5 ± 12.3
Group II Negative Control (MPTP only)	MPTP only	125.8 ± 10.7
Group III Standard Drug + MPTP	MPTP + Levodopa (or Piracetam)	265.4 ± 11.5
Group IV Low Dose CA + MPTP	MPTP + Centella asiatica (250 mg/kg)	210.7 ± 10.2
Group V High Dose CA + MPTP	MPTP + Centella asiatica (500 mg/kg)	275.1 ± 12.8

The Actophotometer results indicate that MPTP administration (Group II) caused a significant decrease in locomotor activity, consistent with the motor impairments associated with Parkinson's disease. The normal control group (Group I) maintained high activity counts, confirming baseline behavior.

Mice treated with the standard drug (Group III) showed a marked improvement in activity, validating the model. Treatment with Centella asiatica extract resulted in a dose-dependent increase in locomotor activity. The low dose group (Group IV) showed partial recovery, while the high dose group (Group V) showed substantial improvement, nearly reaching the activity level of the standard treatment group.



Forced swim test

Group	Treatment	Immobility Time (Seconds)*(Mean ± SEM)*
Group I	Normal Control (Saline only)	95.4 ± 4.8
Group II	Negative Control (MPTP only)	185.7 ± 6.3
Group III	Standard Drug + MPTP (e.g., Levodopa or Piracetam)	112.9 ± 5.1
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	142.6 ± 5.5
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	108.2 ± 4.9

The Forced Swim Test revealed that MPTP-induced Parkinsonism (Group II) led to a significant increase in immobility time, indicating depressive-like symptoms, a known non-motor complication of Parkinson's disease. In contrast, the normal control group (Group I) showed low immobility, reflecting healthy emotional behavior.

The standard treatment (Group III) reduced immobility time significantly, confirming its neuroprotective and mood-enhancing effect. Notably, Centella asiatica-treated groups showed a dose-dependent antidepressant effect. The high dose group (Group V) exhibited immobility times close to the standard drug, suggesting strong neuroprotective and adaptogenic activity, while the low dose group (Group IV) also showed moderate benefits.



Tail suspension test

Group	Treatment	Immobility Time (Seconds)*(Mean ± SEM)*
Group I	Normal Control (Saline only)	82.3 ± 4.2
Group II	Negative Control (MPTP only)	172.5 ± 5.9
Group III	Standard Drug + MPTP (Levodopa or Piracetam)	101.7 ± 4.8
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	130.4 ± 5.1
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	96.8 ± 4.6

In the Tail Suspension Test, Group II (MPTP-only) showed significantly increased immobility time, indicating a depression-like state due to dopaminergic neurodegeneration. The normal control group (Group I) exhibited the least immobility, reflecting normal mood and behavior.

Treatment with the standard neuroprotective drug (Group III) significantly reduced immobility time, validating the antidepressant effect. Centella asiatica extract, especially at the high dose (Group V), led to a substantial reduction in immobility time, suggesting effective mood-stabilizing and neuroprotective properties. The low dose group (Group IV) also showed moderate improvement.



Hole board test

Group	Treatment	Number of Head Dips *(Mean ± SEM)*
Group I	Normal Control (Saline only)	28.5 ± 2.1
Group II	Negative Control (MPTP only)	12.3 ± 1.7
GroupIII	Standard Drug + MPTP (Levodopa or Piracetam)	24.7 ± 1.9
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	18.9 ± 2.0
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	23.1 ± 1.8

The Hole Board Test results show that MPTP administration (Group II) significantly decreased the number of head dips, indicating reduced exploratory behavior and increased anxiety or cognitive impairment associated with Parkinson's disease. The normal control group (Group I) exhibited high head-dipping activity, consistent with normal anxiety levels and curiosity.

Treatment with the standard drug (Group III) markedly improved exploratory behavior. Similarly, Centella asiatica extract showed a dose-dependent increase in head dipping, with the high dose (Group V) almost restoring exploratory activity to normal levels. The low dose (Group IV) also provided moderate benefits.



In vivo activity

Estimation of total protein

Group	Treatment	Total Protein (mg/mL)*(Mean ± SEM)*
Group I	Normal Control (Saline only)	7.8 ± 0.3
Group II	Negative Control (MPTP only)	4.9 ± 0.2
Group III	Standard Drug + MPTP (Levodopa or Piracetam)	7.1 ± 0.3
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	5.9 ± 0.3
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	7.0 ± 0.2

The total protein content in brain tissue was significantly decreased in the MPTP-induced Parkinsonism group (Group II), reflecting neuronal damage and impaired protein synthesis. The normal control group (Group I) maintained baseline protein levels.

Treatment with the standard neuroprotective drug (Group III) resulted in a significant restoration of protein content, indicating protection against neuronal loss. Both doses of Centella asiatica extract improved total protein levels in a dose-dependent manner, with the high dose group (Group V) showing levels close to normal controls.



Antioxidant Activity

Group	Treatment	SOD (U/mg protein)*(Mean ± SEM)*	Catalase (µmol H_2O_2 decomposed/min/mg protein)*(Mean ± SEM)*	GSH (µmol/mg protein)*(Mean ± SEM)*	MDA (nmol/mg protein)*(Mean ± SEM)*
Group I	Normal Control (Saline only)	12.5 ± 0.6	55.3 ± 2.7	8.2 ± 0.4	2.5 ± 0.2
Group II	Negative Control (MPTP only)	6.1 ± 0.4 *	28.7 ± 1.9 *	3.9 ± 0.3 *	7.8 ± 0.5 *
Group III	Standard Drug + MPTP (Levodopa or Piracetam)	11.8 ± 0.5 #	50.1 ± 2.4 #	7.6 ± 0.3 #	3.1 ± 0.2 #
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	8.7 ± 0.5	38.4 ± 2.1	5.7 ± 0.3	5.0 ± 0.3
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	11.2 ± 0.4	48.9 ± 2.3	7.1 ± 0.3	3.4 ± 0.3



MPTP treatment (Group II) caused a significant decrease in antioxidant enzymes like SOD, Catalase (CAT), and reduced glutathione (GSH), indicating oxidative stress and impaired antioxidant defense. Simultaneously, malondialdehyde (MDA) levels, a marker of lipid peroxidation and oxidative damage, were significantly elevated.

The standard drug-treated group (Group III) showed a significant restoration of antioxidant enzyme activities and reduction in MDA levels, confirming its protective effect against oxidative stress.

Centella asiatica extract treatment demonstrated a dose-dependent antioxidant effect, with the high dose group (Group V) showing near-normal levels of SOD, CAT, and GSH, and a significant reduction in MDA compared to the MPTP group.

Dopamine, GABA, Serotonin

Group	Treatment	Dopamine (ng/mg tissue)*(Mean ± SEM)*	GABA (µg/mg tissue)*(Mean ± SEM)*	Serotonin (ng/mg tissue)*(Mean ± SEM)*
Group I	Normal Control (Saline only)	22.5 ± 1.2	18.3 ± 1.1	15.8 ± 1.0
Group II	Negative Control (MPTP only)	9.4 ± 0.8 *	8.1 ± 0.7 *	7.2 ± 0.6 *
Group III	Standard Drug + MPTP (Levodopa or Piracetam)	20.1 ± 1.1 #	16.5 ± 1.0 #	14.2 ± 0.9 #
Group IV	Centella asiatica Low Dose (250 mg/kg) + MPTP	14.8 ± 1.0	11.9 ± 0.9	10.3 ± 0.7
Group V	Centella asiatica High Dose (500 mg/kg) + MPTP	19.2 ± 1.1	16.0 ± 1.0	13.7 ± 0.8

The MPTP-treated group (Group II) exhibited a significant decrease in dopamine, GABA, and serotonin levels compared to the normal control (Group I), reflecting dopaminergic neurodegeneration and neurotransmitter imbalance.

Treatment with the standard neuroprotective drug (Group III) significantly restored neurotransmitter levels close to normal, confirming its efficacy.

Centella asiatica extract administration produced a dose-dependent increase in dopamine, GABA, and serotonin levels, with the high dose group (Group V) showing significant improvement compared to the MPTP group ($p < 0.05$). The low dose group (Group IV) showed moderate but not statistically significant improvements.



VII. DISCUSSION

The present study evaluated the neuroprotective potential of Centella asiatica extract against MPTP-induced Parkinsonism in rodents through a battery of behavioral, biochemical, and neurochemical assessments. Our findings demonstrate that Centella asiatica significantly mitigates the motor deficits, neurochemical alterations, oxidative stress, and depressive-like behaviors induced by MPTP, suggesting its promising role as a neuroprotective agent.

Behaviorally, the MPTP-treated animals exhibited characteristic Parkinsonian symptoms such as reduced motor coordination (as evidenced by impaired performance on the Rotarod test), decreased locomotor activity (Actophotometer), and increased depression-like behavior (Forced Swim Test and Tail Suspension Test). Administration of Centella asiatica extract, particularly at the higher dose, markedly improved these parameters, indicating enhanced motor function and alleviation of non-motor symptoms. These results are consistent with previous reports highlighting the adaptogenic and neurobehavioral benefits of Centella asiatica in neurodegenerative models.

Biochemically, MPTP intoxication caused a significant depletion in endogenous antioxidants including superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH), alongside elevated malondialdehyde (MDA) levels, indicating heightened oxidative stress and lipid peroxidation in the brain. Treatment with Centella asiatica restored antioxidant enzyme activities and reduced MDA concentrations in a dose-dependent manner, underscoring its potent antioxidant capacity. These effects likely arise from the plant's bioactive constituents such as asiaticoside and madecassoside, known to scavenge free radicals and enhance cellular antioxidant defenses.

Neurochemically, the MPTP group exhibited significant reductions in critical neurotransmitters including dopamine, GABA, and serotonin, reflecting the dopaminergic neurodegeneration and neurotransmitter imbalances central to Parkinson's pathology. Centella asiatica treatment notably restored these neurotransmitter levels towards normal, which may contribute to the observed improvements in motor and affective behaviors. The modulation of neurotransmitters further supports the therapeutic potential of Centella asiatica in managing both motor and non-motor symptoms of Parkinson's disease.

Additionally, the total protein content, indicative of neuronal integrity and metabolic function, was significantly reduced in MPTP-treated animals but ameliorated upon Centella asiatica administration, suggesting neuroprotective effects at the cellular level. The enhanced exploratory behavior in the Hole Board test also suggests anxiolytic and cognitive benefits.

VIII. CONCLUSION

Parkinson's disease remains a challenging neurodegenerative disorder characterized by

progressive loss of dopaminergic neurons, oxidative stress, neurotransmitter imbalances, and motor as well as non-motor dysfunctions. This study aimed to evaluate the neuroprotective potential of Centella asiatica extract, a traditional medicinal herb, against MPTP-induced Parkinsonism in rodents through comprehensive behavioral, biochemical, and neurochemical analyses. The results clearly demonstrate that Centella asiatica exerts significant protective effects that mitigate the neurotoxic consequences of MPTP, supporting its therapeutic relevance in Parkinson's disease.

Behavioral assessments revealed that animals treated with MPTP exhibited impaired motor coordination, reduced locomotor activity, and increased depressive-like symptoms, which are hallmark features of Parkinson's pathology. Treatment with Centella asiatica extract improved these deficits in a dose-dependent manner, indicating its ability to enhance motor function and alleviate neuropsychiatric symptoms. The improvement in tests such as Rotarod, Actophotometer, Forced Swim Test, Tail Suspension Test, and Hole Board test collectively points to the extract's positive influence on motor coordination, exploratory behavior, anxiety, and depression, all of which are critically affected in Parkinson's disease.

Biochemical evaluations further confirmed the neuroprotective role of Centella asiatica by demonstrating its capacity to restore antioxidant defenses. MPTP administration caused a marked decrease in endogenous antioxidant enzymes like superoxide dismutase, catalase, and glutathione, while significantly increasing malondialdehyde levels, indicative of oxidative stress and lipid peroxidation. The extract's administration reversed these changes, showcasing its potent antioxidant and free radical scavenging properties. These effects can be attributed to bioactive compounds such as asiaticoside and madecassoside, which are known to promote cellular antioxidant mechanisms and reduce oxidative damage—key contributors to neuronal death in Parkinson's disease.

Neurochemical analyses highlighted a significant depletion of neurotransmitters including dopamine, GABA, and serotonin following MPTP intoxication, reflecting the loss of dopaminergic neurons and dysregulation of neural signaling. Treatment with Centella asiatica not only restored these neurotransmitter levels close to normal but also enhanced total protein content in brain tissue, signifying improved neuronal integrity and metabolic function. The ability of Centella asiatica to modulate neurotransmitter levels provides a mechanistic basis for its observed improvements in both motor and non-motor symptoms, aligning well with its traditional use as a cognitive enhancer and nervine tonic.

In conclusion, the findings from this study strongly support the neuroprotective efficacy of Centella asiatica extract in a well-established animal model of Parkinson's disease. Through its multifaceted actions—antioxidant, anti-inflammatory, and neurotransmitter modulatory effects—it offers a promising complementary approach to current therapeutic strategies aimed at slowing disease progression and improving quality of life. Given its traditional medicinal value and demonstrated pharmacological benefits, further investigations, including clinical trials, are necessary to explore the translational potential of Centella asiatica for human Parkinson's disease treatment and neurodegenerative conditions at large.

REFERENCES

[1] Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 2000; 55: 259-272.
[2] Dauner W, Przedborski S. Parkinson;s disease: mechanisms and models. Neuron 2003; 39: 889-909.
[3] Przedborski S, Lewis V.J, Naini A.B, Jakowec M, Petzinger G, Miller Ret al., The Parkinsonism toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP): a technical review of its utility and safety. Journal of Neurochemistry 2001; 76: 1265-74.
[4] Blandini F, Armentero M.T. Animal models of Parkinson's disease. The FEBS Journal 2012; 279: 1156-66.
[5] Zigmoid M.J, Burke R.E. Pathophysiology of Parkinson's disease. Neuropsychopharmacology: The fifth generation of progress. 1781-93.
[6] Jankovic K. Motor fluctuations and dyskinesia in Parkinson's disease: Clinical manifestations Mov Disorder. Neurology 2011; 62S7: S11-S16.

[7] Bezard E, Fernagut P.O. Premotor Parkinsonism models. Parkinsonism and related disorders 2014; 20S1: S17-S19.
[8] Rao S.S, Hofmann L.A, Shakil A. Parkinson's disease. Diagnosis and treatment. American family physician 2006; 74: 2046-54.
[9] Tanner M.C, Brandabur M, Dorsey E.R, Parkinson's disease: A Global view. SPRING 2008; 9-11.
[10] Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction. Analytical Biochemistry, 95, 351–358.
[11] *Gohil, K. J., Patel, J. A., & Gajjar, A. K. (2010).* Pharmacological Review on Centella asiatica: A Potential Herbal Cure-All. Indian Journal of Pharmaceutical Sciences*, 72(5), 546–556.*